Total Payments
$143,086
2024 Payments
$11,292
Companies
14
Transactions
112
Medicare Patients
1,296
Medicare Billing
$267,994
Payment Breakdown by Category
Consulting$89,823 (62.8%)
Travel$26,064 (18.2%)
Research$13,935 (9.7%)
Other$11,298 (7.9%)
Food & Beverage$1,966 (1.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $89,823 | 35 | 62.8% |
| Travel and Lodging | $26,064 | 22 | 18.2% |
| Unspecified | $13,935 | 17 | 9.7% |
| Honoraria | $10,000 | 1 | 7.0% |
| Food and Beverage | $1,966 | 35 | 1.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,298 | 2 | 0.9% |
Payments by Type
General
$129,151
95 transactions
Research
$13,935
17 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca UK Limited | $30,158 | 22 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $25,780 | 21 | $0 (2022) |
| PFIZER INC. | $21,309 | 11 | $0 (2023) |
| F. Hoffmann-La Roche AG | $15,233 | 19 | $0 (2024) |
| Daiichi Sankyo Inc. | $14,921 | 4 | $0 (2024) |
| Mirati Therapeutics, Inc. | $13,040 | 11 | $0 (2023) |
| GENZYME CORPORATION | $9,168 | 4 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $5,463 | 9 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $3,657 | 3 | $0 (2018) |
| Novartis Pharmaceuticals Corporation | $1,563 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $11,292 | 15 | E.R. Squibb & Sons, L.L.C. ($5,463) |
| 2023 | $28,750 | 24 | Mirati Therapeutics, Inc. ($13,040) |
| 2022 | $3,504 | 3 | AstraZeneca Pharmaceuticals LP ($2,055) |
| 2021 | $6,486 | 8 | F. Hoffmann-La Roche AG ($4,277) |
| 2020 | $20,182 | 7 | Daiichi Sankyo Inc. ($12,031) |
| 2019 | $30,772 | 24 | PFIZER INC. ($10,149) |
| 2018 | $31,068 | 22 | AstraZeneca UK Limited ($15,059) |
| 2017 | $11,032 | 9 | AstraZeneca Pharmaceuticals LP ($10,946) |
All Payment Transactions
112 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/24/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Consulting Fee | Cash or cash equivalent | $1,640.00 | General |
| Category: ONCOLOGY | ||||||
| 11/06/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,720.00 | General |
| 10/30/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,525.00 | General |
| Category: ONCOLOGY | ||||||
| 09/30/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $1,541.25 | General |
| 09/30/2024 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $365.91 | Research |
| Study: LCMC3: Long-Term Disease-Free and Overall Survival and Their Association With ctDNA After Neoadjuvant Atezolizumab for NSCLC • Category: BioOncology | ||||||
| 06/30/2024 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $715.76 | Research |
| Study: LCMC3 • Category: BioOncology | ||||||
| 04/12/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $130.00 | General |
| 03/22/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| 03/14/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,842.50 | General |
| 03/01/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $134.99 | General |
| 03/01/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $64.99 | General |
| 03/01/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $49.99 | General |
| 03/01/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $27.44 | General |
| 02/29/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $292.67 | General |
| 02/21/2024 | Genentech, Inc. | Tecentriq (Biological) | Food and Beverage | In-kind items and services | $41.84 | General |
| Category: BioOncology | ||||||
| 12/14/2023 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2023 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $1,250.00 | General |
| 09/21/2023 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Consulting Fee | Cash or cash equivalent | $350.00 | General |
| Category: ONCOLOGY | ||||||
| 09/09/2023 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $2,980.00 | General |
| 09/09/2023 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $2,980.00 | General |
| 09/09/2023 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $82.98 | General |
| 08/17/2023 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Consulting Fee | Cash or cash equivalent | $7,000.00 | General |
| Category: ONCOLOGY | ||||||
| 07/22/2023 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Travel and Lodging | Cash or cash equivalent | $499.10 | General |
| Category: ONCOLOGY | ||||||
| 07/22/2023 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Travel and Lodging | Cash or cash equivalent | $292.67 | General |
| Category: ONCOLOGY | ||||||
| 07/22/2023 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $135.00 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE II, OPEN-LABEL, MULTICENTER, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB AS NEOADJUVANT AND ADJUVANT THERAPY IN PATIENTS WITH STAGE IB, II, IIIA RESECTABLE AND UNTREATED NON-SMALL CELL LUNG CANCER NSCLC | F. Hoffmann-La Roche AG | $5,727 | 8 |
| LCMC3 | F. Hoffmann-La Roche AG | $4,107 | 6 |
| Neoadjuvant targeted therapy in resectable non-small cell lung cancer:nsclc current and future perspectives | F. Hoffmann-La Roche AG | $3,191 | 1 |
| NAUTIKA1 previously LCMC4 | F. Hoffmann-La Roche AG | $543.79 | 1 |
| LCMC3: Long-Term Disease-Free and Overall Survival and Their Association With ctDNA After Neoadjuvant Atezolizumab for NSCLC | F. Hoffmann-La Roche AG | $365.91 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 301 | 710 | $397,425 | $61,435 |
| 2022 | 4 | 326 | 881 | $441,670 | $70,959 |
| 2021 | 4 | 361 | 934 | $501,330 | $83,124 |
| 2020 | 5 | 308 | 810 | $393,255 | $52,477 |
Total Patients
1,296
Total Services
3,335
Medicare Billing
$267,994
Procedure Codes
17
All Medicare Procedures & Services
17 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 118 | 394 | $214,730 | $32,066 | 14.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 57 | 111 | $81,030 | $14,072 | 17.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 89 | 168 | $63,000 | $9,267 | 14.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 37 | 37 | $38,665 | $6,029 | 15.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 103 | 370 | $201,650 | $32,392 | 16.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 140 | 411 | $154,125 | $23,918 | 15.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 44 | 61 | $45,140 | $8,159 | 18.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 39 | 39 | $40,755 | $6,490 | 15.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 118 | 392 | $213,640 | $34,305 | 16.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 120 | 350 | $131,250 | $21,256 | 16.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 67 | 136 | $97,920 | $17,996 | 18.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 56 | 56 | $58,520 | $9,566 | 16.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 90 | 269 | $139,880 | $18,602 | 13.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 110 | 370 | $131,350 | $16,950 | 12.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 62 | 124 | $85,560 | $11,450 | 13.4% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 35 | 35 | $35,505 | $5,331 | 15.0% |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m servic | Office | 2020 | 11 | 12 | $960.00 | $144.12 | 15.0% |
About Dr. Mark Kris, MD
Dr. Mark Kris, MD is a Medical Oncology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/29/2006. The National Provider Identifier (NPI) number assigned to this provider is 1174594113.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Kris, MD has received a total of $143,086 in payments from pharmaceutical and medical device companies, with $11,292 received in 2024. These payments were reported across 112 transactions from 14 companies. The most common payment nature is "Consulting Fee" ($89,823).
As a Medicare-enrolled provider, Kris has provided services to 1,296 Medicare beneficiaries, totaling 3,335 services with total Medicare billing of $267,994. Data is available for 4 years (2020–2023), covering 17 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location New York, NY
- Active Since 01/29/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1174594113
Products in Payments
- IMFINZI (Drug) $21,689
- KRAZATI (Drug) $13,040
- VIZIMPRO (Drug) $11,399
- TECENTRIQ (Biological) $7,025
- TAGRISSO (Drug) $5,143
- Tecentriq (Biological) $4,515
- Alecensa (Biological) $3,735
- LIBTAYO CEMIPLIMAB-RWLC INJECTION (Biological) $3,657
- LIBTAYO (Biological) $3,125
- Enhertu (Drug) $1,640
- TABRECTA (Drug) $1,563
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in New York
Craig Thompson, Md, MD
Medical Oncology — Payments: $2.1M
Medical Oncology $2.1M
Andrew Seidman, Md, MD
Medical Oncology — Payments: $1.7M
Medical Oncology $1.7M
Dr. Joshua Richter, M.d, M.D
Medical Oncology — Payments: $1.6M
Medical Oncology $1.6M
Ghassan Abou-Alfa, Md, MD
Medical Oncology — Payments: $1.2M
Medical Oncology $1.2M
Edward Gelmann
Medical Oncology — Payments: $944,679
Medical Oncology $944,679
Miguel Perales, Md, MD
Medical Oncology — Payments: $759,555
Medical Oncology $759,555